FDA Approves New Treatment for Advanced Soft Tissue Sarcoma

Share this content:
FDA Approves New Treatment for Advanced Soft Tissue Sarcoma
FDA Approves New Treatment for Advanced Soft Tissue Sarcoma

WEDNESDAY, Oct. 19, 2016 (HealthDay News) -- Lartruvo (olaratumab) has been approved by the U.S. Food and Drug Administration to treat adults with certain soft tissue sarcomas.

Lartruvo, a platelet-derived growth factor receptor-alpha blocking antibody, has been sanctioned for use with doxorubicin in cases that cannot be treated with radiation or surgery, the FDA said Wednesday in a news release.

The drug was evaluated in clinical trials involving 133 patients with soft tissue carcinomas. Average survival among patients who took Lartruvo and doxorubicin was 8.2 months, compared with 4.4 months among patients who took doxorubicin alone. Potential side effects identified during the studies included harm to a developing fetus, hypotension, fever, chills, nausea, fatigue, neutropenia, and musculoskeletal pain.

Lartruvo's maker, Indianapolis-based Eli Lilly and Company, is conducting a larger study to further evaluate the drug's effectiveness among numerous types of soft tissue sarcoma, the agency said.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Clinician Awareness of Exercise Addiction May Be Lacking

Clinician Awareness of Exercise Addiction May Be Lacking

Screening questions should focus on emotional connection to exercise, whether it interferes with life

Overall Vagotomy Not Linked to Risk of Parkinson's Disease

Overall Vagotomy Not Linked to Risk of Parkinson's ...

But there is a trend toward lower risk of Parkinson's for patients with truncal vagotomy

Pediatricians Missing Elevated Blood Lead Levels in U.S.

Pediatricians Missing Elevated Blood Lead Levels in U.S.

In 23 of 39 reporting states, pediatric care providers identified fewer than half of children with EBLL

is free, fast, and customized just for you!

Already a member?

Sign In Now »